News headlines about Derma Sciences (NASDAQ:DSCI) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Derma Sciences earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 44.674786954103 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-derma-sciences-dsci-stock-price/1492165.html.

About Derma Sciences

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insider Buying and Selling by Quarter for Derma Sciences (NASDAQ:DSCI)

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.